Noticias y Actividades de TG Therapeutics
Presencia
TG Therapeutics es una de las ...
TG Therapeutics es una empresa que cotiza bajo el símbolo de cotización TGTX (US).
Ejecutivos
Ver el organigrama con sus 9 ejecutivos principales
Biografías más buscadas en TG Therapeutics
- Michael Weiss, Executive Chairman, President and Chief Executive O...
- Laurence Charney, Director
- Kenneth Hoberman, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en TG Therapeutics.
Farmacia
TG Therapeutics tiene 1.834 competidores entre los que se incluyen Pfizer (Estados Unidos), Eli Lilly (Estados Unidos) y Sanofi (Francia).
Popular M&A news in Farmacia
- Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publicado el 12 de marzo de 2025).
- Jazz Pharmaceuticals ha Chimerix adquirido (publicado el 6 de marzo de 2025).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de TG Therapeutics
- TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 8Th Congress of the European Academy of Neurology | TG Therapeutics, Inc.
- TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting | TG Therapeutics, Inc.
- TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS | TG Therapeutics, Inc.
- TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting | TG Therapeutics, Inc.
- TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference | TG Therapeutics, Inc.
- TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference | TG Therapeutics, Inc.
- TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia | TG Therapeutics, Inc.
- RSS News Feeds | TG Therapeutics, Inc.
- TG Therapeutics to Present at Upcoming Investor Conferences | TG Therapeutics, Inc.
- TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma | TG Therapeutics, Inc.
- View more press releases Close
Redes sociales sobre TG Therapeutics
- TG Therapeutics en Wikipedia, Google News y Yahoo Finance
- TG Therapeutics en LinkedIn, Twitter y YouTube
